REG - IXICO plc - Share Option Award & PDMR Dealings

IXICOAnnouncement

04/12/2024 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241204:nRSD8082Oa&default-theme=true

RNS Number : 8082O  IXICO plc  04 December 2024

4 December 2024

 

 

 

IXICO PLC

 

("IXICO" or the "Company")

 

Share Option Award & Director Bed & ISA Dealings

PDMR Dealing

 

Share Option Award:

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neurosciences, today announces that it has issued a
total of 500,000 options to subscribe for ordinary shares of 1 pence each in
the Company (the "Share Options") to Robin Wolz, CSO and a PDMR of the
Company.

 

In recognition of his increasing contribution to the continued success of the
Group, the Board has decided to provide Mr Wolz with share option performance
criteria that is aligned with the Group's Executive Directors.

 

The Share Options have vesting criteria aligned with retention and annual
share price growth over 3 years. These options have an exercise price of
£0.01 and will be subject to a hold period to the third anniversary of their
award.

 

The achievement of share price growth each year shall be measured by
calculating the 3-month average share price immediately prior to each
anniversary of the option award. The growth performance can be met in full by
an absolute compound share price growth of 40% over the three-year period or
in part by a 40% share price growth as compared to the prior year. In the
first year this shall be compared to a baseline price equivalent to the
three-month average share price immediately prior to the CEO joining the
Company on 19 August 2024.

 

It is further announced that 200,000 options awarded to Mr Wolz on 30 October
2024 lapsed in full with effect from 28 November 2024.

 

Director Bed & ISA Dealings:

 

In addition, the Company announces that it received notification on 4 December
2024, that Grant Nash, CFO and PDMR, sold 260,000 ordinary shares of 1p each
in the Company and repurchased 260,000 ordinary shares into Mr Nash's ISA
account.  Following this transaction Mr Nash's beneficial interest in the
Company's shares has not changed.

 

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.

 

 

For further information please contact:

 

 IXICO plc                                           +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited                   +44 (0) 20 7220 0500

 (Nominated adviser and sole broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks (Life Sciences Specialist Sales)
 Harriet Ward (Corporate Broking)
 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on X (formerly Twitter) @IXICOnews

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Robin Wolz

 2    Reason for the notification

 a)   Position/status                                              Chief Scientific Officer and PDMR

 b)   Initial notification /Amendment                              Initial

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         IXICO plc

 b)   LEI                                                          2138005M1F59O6HWSA97

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares in IXICO plc

      Identification code                                          ISIN: GB00BFXR4C20

 b)   Nature of the transaction                                    Grant of Share Options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     1 pence           500,000

 d)   Aggregated information

                                                                   N/A - single transaction
      - Aggregated volume

      - Price

 e)   Date of the transaction                                      4 December 2024

 f)   Place of the transaction                                     Off Market Transaction

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Grant Nash

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer and PDMR

 b)   Initial notification /Amendment                              Initial

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         IXICO plc

 b)   LEI                                                          2138005M1F59O6HWSA97

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares in IXICO plc

      Identification code                                          ISIN: GB00BFXR4C20

 b)   Nature of the transaction                                    Sale and purchase of ordinary shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)             Volume(s)
                                                                                     Sale at 12.000p      260,000
                                                                                     Purchase at 12.015p  260,000

 d)   Aggregated information

                                                                   N/A
      - Aggregated volume

      - Price

 e)   Date of the transaction                                      4 December 2024

 f)   Place of the transaction                                     Off Market Transaction

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFSDFFLELSEDE